Highlights
- 1Dermatitis : contact, atopic, occupational, drug · 2023
- 2
- 3
Publications
220 publications
Funding
2 grants
Active
2 grants- PI2026-FEL-700486Fellowship for WCM Englander Department of Dermatology Center for Diverse Skin ComplexionsAbbVie Inc. · 2026–2027
- PIFEL-67090FEL-CFG-2025 - Fellowship for WCM Englander Department of Dermatology Center for Diverse Skin ComplexionsAbbVie Inc. · 2025–2026
Clinical research
11 studies
Active
4 studies- PINCT07108283A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants With Nonsegmental VitiligoPHASE2 · Takeda Development Center Americas, Inc. · OPEN TO ACCRUAL (as of 2026)Nonsegmental Vitiligo
- PINCT06863961A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients With Moderate to Severe Atopic DermatitisPHASE2 · F. Hoffman La-Roche Ltd · OPEN TO ACCRUAL (as of 2025)Atopic Dermatitis
- PINCT06389136A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)PHASE3 · AbbVie Inc. · OPEN TO ACCRUAL (as of 2025)Atopic Dermatitis
- PIRetrospective Analysis of Clinical Presentations and Risk Factors for Central Centrifugal Cicatricial Alopecia in MenWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
Completed & closed trials (7)
- PIRetrospective Analysis of Hair Care Practices, Diagnosis, and Treatment for Central Centrifugal Cicatricial Alopecia, Traction Alopecia, Pseudofolliculitis Barbae, and Acne Keloidalis NuchaeWeill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2026)
- PICastle Biosciences, Inc. Inflammatory Skin Disease Treatment Identification StudyCastle Biosciences, Inc · IRB STUDY CLOSURE (as of 2026)
- PISKM21-HYP-02 An Open-Label, Single-Center Study to Evaluate the Efficacy and Tolerability of a Topical Serum and Spot Treatment in Skin of Color Subjects with Moderate MelasmaAllergan · IRB STUDY CLOSURE (as of 2025)
- PINCT06113471A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental VitiligoPHASE3 · Incyte Corporation · CLOSED TO ACCRUAL (as of 2025)NonSegmental Vitiligo
- PINCT05704738A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)PHASE3 · Amgen, Inc. · IRB STUDY CLOSURE (as of 2024)Atopic Dermatitis
- PINCT05142774An Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream, 1% in Subjects With Atopic DermatitisPHASE3 · Dermavant Sciences, Inc. · IRB STUDY CLOSURE (as of 2024)Atopic Dermatitis
- PINCT05014568A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and AdultsPHASE3 · Dermavant Sciences, Inc. · IRB STUDY CLOSURE (as of 2023)Atopic Dermatitis
Media highlights
6 clips
- Acne Treatment Goal In Black Patients Includes Addressing Postinflammatory HyperpigmentationMedscape · November 9, 2026
- Rosacea In Dark Skin Types: Not Rare, But UnderdiagnosedMedscape · October 27, 2026
- Does Mentorship Improve Outcomes For Patients Of Color?HCP Live · August 25, 2026
- Why Mentorship Matters Most For Dermatology TraineesHCP Live · August 24, 2026
- Skin Of Color Savvy: Mentorship In Dermatology—Building The Next Generation Of LeadersHCP Live · August 18, 2026
Show 1 more mention
- Experts Weigh Vitiligo's Cosmetic Label As Oral Therapies NearAmerican Journal of Managed Care · August 17, 2026
External relationships
Advisory/Scientific Board Member
AbbVie Inc. · Arcutis Biotherapeutics, Inc. · Bausch Health · Eli Lilly and Company · Galderma S.A. · Incyte, Inc. · L'Oreal USA · Novartis Pharmaceuticals Corporation · Pfizer, Inc. · Regeneron Pharmaceuticals, Inc. · Sanofi S.A. · Veradermics INC
Other Interest
Castle Biosciences, Inc
Other
AbbVie Inc. · Alumis INC · Apogee Pharmaceuticals, INC · Arcutis Biotherapeutics, Inc. · Bristol-Myers Squibb Company · Dermavant Sciences, Inc. · Eli Lilly and Company · Galderma S.A. · Genentech, Inc. · Janssen Global Services, LLC · Johnson & Johnson · LEO Pharma Inc. · Pfizer, Inc. · Regeneron Pharmaceuticals, Inc. · UCB Pharma, Inc.